No price history available.
Key financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SEKm | N/A | 9,354 | 11,718 | 13,453 | 15,025 | 16,787 | N/A | N/A |
| Operating profit | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SEKm | N/A | 467 | 430 | 203 | 360 | 492 | N/A | N/A |
| EPS reported | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SEKm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SEK | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SEK| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion supplies, and wound dressings, alongside advanced medical apparatus like endoscopy systems, incubators, and ventilators. They also distribute pharmaceuticals and offer diagnostic instruments for conditions including diabetes and hypertension. The company equips operating rooms, polyclinics, and day surgery facilities with specialized medical devices, and provides veterinary equipment, hygiene solutions, and targeted products for urology, ultrasound diagnostics, laser treatment, and regenerative medicine. Additionally, their offerings include defibrillators, advanced wound care products, and critical protection and trauma supplies for emergency services, law enforcement, and military personnel, as well as products for beauty clinics. Beyond their core product range, Asker Healthcare Group develops and markets proprietary disposable medical items under the Evercare, Selefa, and Embra brands, and serves as a key distributor of ophthalmic surgical products. They also create and sell innovative solutions for time management, communication, and cognitive support, aimed at schools, assistive technology centers, and various public services. The group extends its offerings to a variety of patient support services, including specialized assistance for wound, diabetes, and urological care, in addition to ostomy, urology, and rehabilitation programs. They supply products for physiotherapy practices, provide exercise and treatment equipment, and offer both sales and rentals of mobility aids and rehabilitation devices, including pressure-relieving mattresses and cushions, which they also manufacture and distribute. Ambulance services are another facet of their diverse operations. Founded in 2018 and headquartered in Danderyd, Sweden, Asker Healthcare Group AB maintains an extensive operational presence across numerous European countries, specifically Sweden, Norway, Finland, Estonia, Latvia, Lithuania, the Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, the Czech Republic, and Poland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Asker Healthcare Group AB (ASKER.ST)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Asker Healthcare Group AB is a comprehensive provider of medical supplies, equipment, and related solutions, all designed to enhance patient care. Their broad product portfolio encompasses essential consumables such as protective items, infusion supplies, and wound dressings, alongside advanced medical apparatus like endoscopy systems, incubators, and ventilators. They also distribute pharmaceuticals and offer diagnostic instruments for conditions including diabetes and hypertension. The company equips operating rooms, polyclinics, and day surgery facilities with specialized medical devices, and provides veterinary equipment, hygiene solutions, and targeted products for urology, ultrasound diagnostics, laser treatment, and regenerative medicine. Additionally, their offerings include defibrillators, advanced wound care products, and critical protection and trauma supplies for emergency services, law enforcement, and military personnel, as well as products for beauty clinics. Beyond their core product range, Asker Healthcare Group develops and markets proprietary disposable medical items under the Evercare, Selefa, and Embra brands, and serves as a key distributor of ophthalmic surgical products. They also create and sell innovative solutions for time management, communication, and cognitive support, aimed at schools, assistive technology centers, and various public services. The group extends its offerings to a variety of patient support services, including specialized assistance for wound, diabetes, and urological care, in addition to ostomy, urology, and rehabilitation programs. They supply products for physiotherapy practices, provide exercise and treatment equipment, and offer both sales and rentals of mobility aids and rehabilitation devices, including pressure-relieving mattresses and cushions, which they also manufacture and distribute. Ambulance services are another facet of their diverse operations. Founded in 2018 and headquartered in Danderyd, Sweden, Asker Healthcare Group AB maintains an extensive operational presence across numerous European countries, specifically Sweden, Norway, Finland, Estonia, Latvia, Lithuania, the Netherlands, Belgium, Luxembourg, Denmark, the United Kingdom, Ireland, Germany, Austria, Switzerland, the Czech Republic, and Poland.
